STAT+: Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial

Ultragenyx said its experimental therapy for Angelman syndrome, a rare disease, showed no benefit compared to a sham treatment in a Phase 3 trial.

Original reporting by STAT · Jason Mast. GridIndex is an aggregation and intelligence layer — full credit to the original publisher.